Status: Recruiting
GD2/CD56 Bi-specific CAR-T Cell Therapy
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in patients.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 1-75Biological sex: AllType: InterventionalSponsor: Shenzhen Geno-Immune Medical InstituteUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
Patients with tumors received standard first-line therapy and have been judged t... [+16]
Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases,... [+7]